Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Aurobindo Pharma Q3...

    Aurobindo Pharma Q3 profit rises 19.69 percent to Rs 712 crore on robust sales

    GarimaWritten by Garima Published On 2019-02-09T09:30:06+05:30  |  Updated On 9 Feb 2019 9:30 AM IST
    Aurobindo Pharma Q3 profit rises 19.69 percent to Rs 712 crore on robust sales

    Commenting on the results, Aurobindo Pharma MD N Govindarajan said: "We have delivered robust revenue growth of 22 per cent, driven by strong growth across all business segments and markets".


    New Delhi: Drug firm Aurobindo Pharma on Thursday reported a 19.69 per cent rise in its consolidated net profit to Rs 712.2 crore for the third quarter ended December 31, mainly on account of robust sales.


    The company had posted a net profit after JV share and minority interest of Rs 595 crore in the corresponding period previous financial year, Aurobindo Pharma said in a BSE filing.


    Consolidated total revenue from operations stood at Rs 5,269.67 crore for the quarter under consideration as against Rs 4,336.11 crore in the same period a year ago.


    Read Also: Aurobindo recalls nearly 5 lakh bottles of blood pressure drug in the US


    The company's board has approved a second interim dividend of Rs 1.25 per equity share of rupee 1 for the year FY18-19, Aurobindo Pharma said.


    Commenting on the results, Aurobindo Pharma MD N Govindarajan said: "We have delivered robust revenue growth of 22 per cent, driven by strong growth across all business segments and markets".


    Gross profit could have been better, but for certain one-time expenses, he added.


    "Our execution strength, pipeline evolution and recent acquisitions will drive the future growth," Govindarajan said.


    In a separate filing, the company said it has entered into a share subscription agreement to invest Rs 15 crore in Synergy Remedies by subscribing to additional equity shares. After making the said investment, Aurobindo Pharma will be holding 19.9 per cent of the share capital of Synergy, it added.


    Read Also: Building a speciality portfolio of around 150 products in the next 3 fiscal yrs: Aurobindo

    AurobindoAurobindo PharmaAurobindo Pharma Q3 earningsAurobindo Pharma Q3 expensesAurobindo Pharma Q3 net profitAurobindo Pharma Q3 resultsAurobindo Pharma Q3 revenueAurobindo Pharma Q3 salesAurobindo Pharma third quarter profitBSEconsolidated net profitDrug firm Aurobindo Pharmainterim dividendN Govindarajanrobust salesShares of Aurobindo Pharma
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok